In practice, because the FDA governs drug approvals in the United States and most Western countries follow similar regulatory frameworks, the 27 threshold remains the functional standard for clinical practice
Decreased appetite was reported by 11-31% among retatrutide-treated subjects (vs 9% placebo) in the obesity trial and by 10% (vs 2% placebo) in the diabetes trial [3,4]
Toxicity is usually due to exceeding the recommended daily dosage, often occurring due to accidental combination use of multiple products containing acetaminophen or through changes in dosage amounts by manufacturers
This work was supported by grants from the NIH, NSF, DOD, ACS, the National Foundation for Cancer Research and the Whitaker Foundation (R.K.J.), and from the VIB, FWO, Biomed and the VLK (P.C.)
Some individuals may feel discouraged if results are not immediate
Joint pain and hair thinning push others toward discontinuation